Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$76.26 -0.4%	$80.58	$57.52 ▼ $93.25	$29.95B	1.48	3.93 million shs	2.43 million shs
FSNUY Fresenius SE & Co.	$14.17 +0.9%	$13.01	$8.48 ▼ $14.20	N/A	0.82	47,214 shs	12,893 shs
PODD Insulet	$322.14 -3.0%	$313.09	$225.37 ▼ $353.50	$22.71B	1.36	745,638 shs	482,151 shs
RMD ResMed	$273.27 +0.2%	$274.97	$199.92 ▼ $293.81	$40.03B	0.85	995,638 shs	213,225 shs
TFX Teleflex	$126.68 +0.7%	$121.28	$108.90 ▼ $249.90	$5.60B	1.08	773,280 shs	130,248 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	+1.28%	-2.36%	-5.44%	-5.51%	+9.22%
FSNUY Fresenius SE & Co.	+0.93%	+1.01%	+3.92%	+16.32%	+46.86%
PODD Insulet	-2.40%	-5.86%	+3.38%	+10.05%	+42.00%
RMD ResMed	+0.55%	-2.38%	-4.19%	+8.77%	+8.42%
TFX Teleflex	+0.01%	-3.48%	+3.93%	+6.82%	-48.86%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$76.26 -0.4%	$80.58	$57.52 ▼ $93.25	$29.95B	1.48	3.93 million shs	2.43 million shs
FSNUY Fresenius SE & Co.	$14.17 +0.9%	$13.01	$8.48 ▼ $14.20	N/A	0.82	47,214 shs	12,893 shs
PODD Insulet	$322.14 -3.0%	$313.09	$225.37 ▼ $353.50	$22.71B	1.36	745,638 shs	482,151 shs
RMD ResMed	$273.27 +0.2%	$274.97	$199.92 ▼ $293.81	$40.03B	0.85	995,638 shs	213,225 shs
TFX Teleflex	$126.68 +0.7%	$121.28	$108.90 ▼ $249.90	$5.60B	1.08	773,280 shs	130,248 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	+1.28%	-2.36%	-5.44%	-5.51%	+9.22%
FSNUY Fresenius SE & Co.	+0.93%	+1.01%	+3.92%	+16.32%	+46.86%
PODD Insulet	-2.40%	-5.86%	+3.38%	+10.05%	+42.00%
RMD ResMed	+0.55%	-2.38%	-4.19%	+8.77%	+8.42%
TFX Teleflex	+0.01%	-3.48%	+3.93%	+6.82%	-48.86%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.91	Moderate Buy	$99.89	30.81% Upside
FSNUY Fresenius SE & Co.	3.33	Buy	N/A	N/A
PODD Insulet	2.89	Moderate Buy	$335.12	5.32% Upside
RMD ResMed	2.82	Moderate Buy	$278.36	2.01% Upside
TFX Teleflex	2.00	Hold	$141.57	12.02% Upside

Current Analyst Ratings Breakdown

Latest RMD, DXCM, TFX, FSNUY, and PODD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2025	DXCM DexCom	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
9/8/2025	PODD Insulet	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$324.00 ➝ $365.00
9/2/2025	RMD ResMed	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform
8/21/2025	DXCM DexCom	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$100.00
8/21/2025	PODD Insulet	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$266.00 ➝ $300.00
8/13/2025	FSNUY Fresenius SE & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/8/2025	PODD Insulet	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$331.00 ➝ $353.00
8/8/2025	PODD Insulet	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$330.00 ➝ $350.00
8/8/2025	PODD Insulet	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$330.00 ➝ $350.00
8/7/2025	PODD Insulet	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/7/2025	PODD Insulet	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.03B	7.43	$2.27 per share	33.63	$5.38 per share	14.19
FSNUY Fresenius SE & Co.	$23.63B	N/A	$1.31 per share	10.77	$9.83 per share	N/A
PODD Insulet	$2.07B	10.81	$4.15 per share	76.70	$17.27 per share	18.42
RMD ResMed	$5.15B	7.76	$11.27 per share	24.21	$40.70 per share	6.70
TFX Teleflex	$3.05B	1.83	$25.48 per share	4.96	$92.11 per share	1.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$576.20M	$1.44	53.04	31.04	1.58	13.29%	30.41%	10.08%	10/23/2025 (Estimated)
FSNUY Fresenius SE & Co.	$509.67M	$0.53	26.68	15.37	N/A	5.09%	9.33%	4.31%	11/5/2025 (Estimated)
PODD Insulet	$418.30M	$3.29	97.05	64.02	2.83	10.01%	23.78%	9.30%	11/6/2025 (Estimated)
RMD ResMed	$1.40B	$9.51	28.69	26.34	1.81	27.22%	25.62%	18.69%	10/23/2025 (Estimated)
TFX Teleflex	$69.68M	$4.25	29.74	8.33	1.76	6.31%	15.08%	8.85%	10/30/2025 (Estimated)

Latest RMD, DXCM, TFX, FSNUY, and PODD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	PODD Insulet	$0.92	$1.17	+$0.25	$0.32	$612.31 million	$649.10 million
8/6/2025	Q2 2025	FSNUY Fresenius SE & Co.	$0.2182	$0.24	+$0.0218	$0.16	$5.83 billion	$6.48 billion
7/31/2025	Q4 2025	RMD ResMed	$2.47	$2.55	+$0.08	$2.58	$1.33 billion	$1.35 billion
7/31/2025	Q2 2025	TFX Teleflex	$3.36	$3.73	+$0.37	$2.77	$771.53 million	$780.90 million
7/30/2025	Q2 2025	DXCM DexCom	$0.45	$0.48	+$0.03	$0.45	$1.13 billion	$1.16 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
FSNUY Fresenius SE & Co.	$0.19	1.34%	N/A	35.85%	N/A
PODD Insulet	N/A	N/A	N/A	N/A	N/A
RMD ResMed	$2.40	0.88%	N/A	25.24%	13 Years
TFX Teleflex	$1.36	1.08%	N/A	32.00%	N/A

Latest RMD, DXCM, TFX, FSNUY, and PODD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2025	RMD ResMed	quarterly	$0.60	0.88%	8/14/2025	8/14/2025	9/18/2025
7/31/2025	TFX Teleflex	quarterly	$0.34	1.19%	8/15/2025	8/15/2025	9/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.48	1.52	1.35
FSNUY Fresenius SE & Co.	0.49	1.31	1.00
PODD Insulet	0.64	2.26	1.81
RMD ResMed	0.11	3.44	2.53
TFX Teleflex	0.42	2.41	1.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
FSNUY Fresenius SE & Co.	N/A
PODD Insulet	N/A
RMD ResMed	54.98%
TFX Teleflex	95.62%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.32%
FSNUY Fresenius SE & Co.	N/A
PODD Insulet	0.39%
RMD ResMed	0.71%
TFX Teleflex	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	10,300	392.15 million	390.90 million	Optionable
FSNUY Fresenius SE & Co.	176,486	N/A	N/A	Not Optionable
PODD Insulet	3,900	70.39 million	70.12 million	Optionable
RMD ResMed	10,600	146.41 million	145.38 million	Optionable
TFX Teleflex	14,100	44.19 million	43.57 million	Optionable

RMD, DXCM, TFX, FSNUY, and PODD Headlines

Recent News About These Companies

Strs Ohio Purchases New Shares in Teleflex Incorporated $TFX

September 17 at 3:26 AM | marketbeat.com

Teleflex Incorporated (TFX) Plans 2026 Split into Two Independent Companies

September 16 at 9:32 AM | insidermonkey.com

Teleflex (NYSE:TFX) Downgraded by Wall Street Zen to Buy

September 16 at 2:09 AM | americanbankingnews.com

Teleflex (NYSE:TFX) Cut to Buy at Wall Street Zen

September 16 at 2:05 AM | marketbeat.com

Should Value Investors Buy Teleflex (TFX) Stock?

September 15 at 10:41 AM | zacks.com

Teleflex In 2025: A Company Trying To Reset

September 14 at 9:11 AM | seekingalpha.com

United Services Automobile Association Makes New Investment in Teleflex Incorporated $TFX

September 14 at 4:02 AM | marketbeat.com

MetLife Investment Management LLC Lowers Position in Teleflex Incorporated $TFX

September 13, 2025 | marketbeat.com

The past five years for Teleflex (NYSE:TFX) investors has not been profitable

September 12, 2025 | finance.yahoo.com

Teleflex says first patient enrolled in DUBSTENT DIABETES trial

September 11, 2025 | msn.com

Teleflex enrolls first patient in dual-drug-eluting device study of coronary interventions for diabetes

September 11, 2025 | massdevice.com

1 Safe-and-Steady Stock on Our Buy List and 2 We Find Risky

September 11, 2025 | msn.com

Teleflex Incorporated Initiates DUBSTENT DIABETES Trial to Evaluate Dual-Device Strategy for PCI in Diabetic Patients

September 11, 2025 | quiverquant.comQ

First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients

September 11, 2025 | globenewswire.com

Teleflex Incorporated (TFX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

September 10, 2025 | seekingalpha.com

Teleflex’s Strategic Integration with BioTronik: A Buy Rating Driven by Market Expansion and Synergy Opportunities

September 10, 2025 | tipranks.com

Sepio Capital LP Purchases 3,034 Shares of Teleflex Incorporated $TFX

September 10, 2025 | marketbeat.com

Millennium Management LLC Boosts Holdings in Teleflex Incorporated $TFX

September 10, 2025 | marketbeat.com

Corebridge Financial Inc. Has $250,000 Holdings in Teleflex Incorporated $TFX

September 10, 2025 | marketbeat.com

AQR Capital Management LLC Buys 20,225 Shares of Teleflex Incorporated $TFX

September 9, 2025 | marketbeat.com

Teleflex (NYSE:TFX) Upgraded by Wall Street Zen to "Strong-Buy" Rating

September 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RMD, DXCM, TFX, FSNUY, and PODD Company Descriptions

DexCom NASDAQ:DXCM

$76.26 -0.30 (-0.39%)

As of 12:54 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Fresenius SE & Co. OTCMKTS:FSNUY

$14.17 +0.13 (+0.93%)

As of 12:36 PM Eastern

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Insulet NASDAQ:PODD

$322.14 -9.99 (-3.01%)

As of 12:54 PM Eastern

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

ResMed NYSE:RMD

$273.27 +0.67 (+0.24%)

As of 12:54 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Teleflex NYSE:TFX

$126.68 +0.86 (+0.68%)

As of 12:53 PM Eastern

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RMD, DXCM, TFX, FSNUY, and PODD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RMD, DXCM, TFX, FSNUY, and PODD Earnings

Compare Dividends

Latest RMD, DXCM, TFX, FSNUY, and PODD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RMD, DXCM, TFX, FSNUY, and PODD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RMD, DXCM, TFX, FSNUY, and PODD Company Descriptions

DexCom NASDAQ:DXCM

Fresenius SE & Co. OTCMKTS:FSNUY

Insulet NASDAQ:PODD

ResMed NYSE:RMD

Teleflex NYSE:TFX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools